Retatrutide: What It Is and What the Trials Show

For three years, tirzepatide held the crown for the most weight a drug could melt off a human body in a clinical trial. Then a triple-hormone molecule from Eli Lilly walked into a Phase 3 study and pulled off something the obesity field had quietly assumed was impossible without a scalpel: an average of roughly 28% of body weight gone, with nearly half of patients on the top dose losing 30% or more. That molecule is retatrutide, and the numbers are the reason every endocrinologist I know has it bookmarked.

Quick answer: Retatrutide is an investigational once-weekly injection from Eli Lilly that activates three gut and metabolic hormone receptors at once (GLP-1, GIP, and glucagon). In trials it produced larger average weight loss than any approved obesity drug to date, up to about 24% in Phase 2 and roughly 28% in Phase 3. It is not yet FDA approved.

What is retatrutide?

Retatrutide (research code LY3437943) is a single engineered peptide that does the work of three. Most of the blockbuster weight-loss drugs you have heard of hit one or two targets. Semaglutide (Wegovy, Ozempic) is a pure GLP-1 agonist. Tirzepatide (Zepbound, Mounjaro) is a dual agonist, hitting GLP-1 and GIP. Retatrutide adds a third lever: the glucagon receptor.

That third receptor is the interesting part, and it is a bit counterintuitive. Glucagon usually raises blood sugar, so adding it to a diabetes-adjacent drug sounds backwards. The bet Lilly made is that glucagon agonism increases energy expenditure, basically nudging the body to burn more fuel, while the GLP-1 and GIP components handle appetite suppression and insulin response. Pull all three at once and you get appetite down and metabolic rate up at the same time (per Lilly’s description of the molecule’s mechanism, lilly.com).

How much weight did people lose on retatrutide?

This is where retatrutide stopped being just another pipeline drug and started making headlines.

The Phase 2 trial, led by Ania Jastreboff and published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity or overweight and no type 2 diabetes. After 48 weeks on the highest dose (12 mg weekly), the average weight loss was about 24.2%, compared with roughly 2.1% for placebo (nejm.org). At the 24-week mark the top dose was already around 17.5% (Eli Lilly). For context, a quarter of body weight is the territory people used to reach only with bariatric surgery.

Then the Phase 3 data landed and somehow raised the bar again. On May 21, 2026, Lilly reported topline results from TRIUMPH-1, a 2,339-patient trial in adults with obesity (or overweight plus a weight-related condition) and no type 2 diabetes. At 80 weeks, mean weight loss reached about 28.3% on the 12 mg dose versus roughly 2.2% on placebo, and 45.3% of those on the top dose lost 30% or more of their starting weight (AJMC). Looked at through the efficacy estimand (patients who stayed on treatment as intended), the figure climbed to about 30.3%.

Put a person to those percentages and it gets vivid. A 230-pound adult losing 28% is down roughly 64 pounds. That is not a slimmer waistline, that is a different body.

Is retatrutide approved yet?

No. As of June 2026, retatrutide is investigational and not approved by the FDA or any other regulator. The only legal way to receive it is by enrolling in one of Lilly’s clinical trials (lilly.com).

Here is the part worth saying plainly, because it matters for safety. Retatrutide’s name is all over the internet right now, sold in vials by “research peptide” sites that ship it as a so-called not-for-human-use chemical. That product is unapproved, unregulated, and not quality-controlled for human injection. You have no guarantee of dose, purity, or sterility. The trial results below come from pharmaceutical-grade material under medical supervision, which is a very different thing from a vial bought online.

The TRIUMPH Phase 3 program is broad: beyond obesity, Lilly is studying retatrutide in type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, cardiovascular and kidney outcomes, and metabolic liver disease (lilly.com). A regulatory filing is expected to follow the completion of these pivotal studies, which realistically puts any approval into the 2027-2028 window. Treat single-date predictions you see online with skepticism, because the FDA timeline is not public.

How does retatrutide compare to tirzepatide and semaglutide?

The honest comparison comes with a caveat editors like me have to flag: these numbers come from separate trials with different patients and durations, so head-to-head conclusions are inference, not proof. Lilly has not run retatrutide directly against tirzepatide. That said, the gap is hard to ignore.

• Semaglutide (Wegovy): in the SURMOUNT-5 head-to-head trial, semaglutide produced about 13.7% average weight loss at 72 weeks (Eli Lilly).
• Tirzepatide (Zepbound): roughly 15% to 21% in SURMOUNT-1 depending on dose, and 20.2% in that same head-to-head SURMOUNT-5 trial.
• Retatrutide: roughly 28% at 80 weeks in TRIUMPH-1, with a sizable share crossing 30%.

The pattern that jumps out is the dose response. In Phase 2, retatrutide showed almost no weight-loss plateau out to 48 weeks, meaning patients were still dropping pounds when the trial ended. That is the signature of a drug whose ceiling we have not found yet.

What are the side effects of retatrutide?

The side effect profile is, in a word, familiar. Retatrutide behaves like the rest of the incretin class. The most common adverse events in both Phase 2 and Phase 3 were gastrointestinal: nausea, vomiting, diarrhea, constipation, and reduced appetite. Most were mild to moderate and tied to how fast the dose was increased (nejm.org).

The dose tells the story on tolerability. In TRIUMPH-1, treatment discontinuations due to side effects rose with the dose: about 4.1% on 4 mg, 6.9% on 9 mg, and 11.3% on 12 mg (AJMC). In other words, the dose that delivers the jaw-dropping weight loss is also the one a meaningful minority of people could not stay on. That trade-off is exactly what the slow titration schedule is built to manage.

One signal worth watching is heart rate. Because of the glucagon component and its effect on metabolism, earlier studies noted dose-dependent increases in heart rate, which is a parameter regulators will scrutinize closely. On the positive side, TRIUMPH-1 reported favorable shifts in cardiometabolic markers including blood pressure, triglycerides, and non-HDL cholesterol.

Frequently asked questions

Is retatrutide the same as Mounjaro or Ozempic?

No. Mounjaro/Zepbound is tirzepatide (a dual GLP-1/GIP agonist) and Ozempic/Wegovy is semaglutide (a single GLP-1 agonist). Retatrutide is a triple agonist that also targets the glucagon receptor, and it is not yet approved or sold as a branded product.

Can I buy retatrutide legally right now?

There is no FDA-approved retatrutide product to buy. Vials sold online as research peptides are unapproved and not quality-controlled for human use, which carries real safety risk. The only sanctioned access is through a clinical trial.

How much weight does retatrutide cause people to lose?

In the Phase 3 TRIUMPH-1 trial, average weight loss was about 28.3% at 80 weeks on the 12 mg dose, with 45.3% of those patients losing 30% or more (AJMC). Individual results vary widely.

When will retatrutide be FDA approved?

No approval date is set. Phase 3 trials are still completing as of 2026, and any filing and review would likely push availability into the 2027-2028 range. Be wary of specific dates posted on supplement or peptide sites.

This article is for general information and is not medical advice. Retatrutide is investigational and not FDA approved. Do not start, stop, or source any weight-loss medication without talking to a licensed clinician who knows your health history.

Reviewed against published trial data from the New England Journal of Medicine, Eli Lilly investor releases, and AJMC reporting on the TRIUMPH-1 Phase 3 results. Last updated June 2026.